1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-(2-oxido-4-oxo-1H-isoindol-2-ium-2-yl)naphthalen-1-yl]urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-(2-oxido-4-oxo-1H-isoindol-2-ium-2-yl)naphthalen-1-yl]urea
• 化学式: C23H16ClN3O5S2
• 分子量: 514.0
• InChiKey: MFNXDNRAIUTWSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PLATELET ADP RECEPTOR INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140221405A1

  公开（公告）日：2014-08-07

  Novel compounds of formulae (I) to (VII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylfulfonamide derivatives which are effective platelet ADF receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  式(I)至式(VII)的新化合物，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰基胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，它们是有效的血小板ADF受体抑制剂。这些衍生物可以用于各种药物组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成相关的疾病，具有显著的疗效。本发明还涉及一种防治哺乳动物血栓形成的方法，包括给予式(I)至式(VIII)化合物或其药学上可接受的盐的治疗有效量。